ProfileGDS5678 / 1448026_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 45% 33% 52% 47% 31% 30% 30% 24% 23% 37% 46% 22% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0317843
GSM967853U87-EV human glioblastoma xenograft - Control 23.0528345
GSM967854U87-EV human glioblastoma xenograft - Control 32.7597133
GSM967855U87-EV human glioblastoma xenograft - Control 43.2131152
GSM967856U87-EV human glioblastoma xenograft - Control 53.0667547
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7690131
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7353730
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6587130
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5421124
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5184923
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.842137
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0435646
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5183722
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9918543